PF-08634404

Phase 3Biologic

Pfizer

PF-08634404 is one of 214 biologic programs targeting Esophageal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

213

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal CancerActive, not recruiting

Intestinal NeoplasmRecruiting

Metastatic Colorectal CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Small Cell Lung Cancer ( SCLC )Recruiting

Advanced Non-Small Cell Lung CancerRecruiting

Carcinoma, Renal CellRecruiting

Carcinoma, HepatocellularRecruiting

Esophageal CancerPhase 2/Phase 3

Active, not recruiting

Intestinal NeoplasmPhase 3

Recruiting

Metastatic Colorectal CancerPhase 3

Active, not recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Hepatocellular CarcinomaPhase 1/Phase 2

Active, not recruiting

Small Cell Lung CancerPhase 2/Phase 3

Active, not recruiting

Small Cell Lung Cancer ( SCLC )Preclinical

Recruiting

Advanced Non-Small Cell Lung CancerPhase 3

Recruiting

Carcinoma, Renal CellPreclinical

Recruiting

Carcinoma, HepatocellularPreclinical

Recruiting

Showing 10 of 12 indications

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

PF-08634404

Pfizer

Phase 3

10 2

PORTRAZZA

Eli Lilly

Preclinical

8 3

Lenvima

Eisai

Preclinical

6 4

Imjudo

AstraZeneca

Preclinical

5 5

Vizimpro

Pfizer

Preclinical

4 6

Remeron

OOrganon and Co

Preclinical

1 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 8

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 9

Treatment

GSK

Preclinical

1 10

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalRecruiting

Urothelial Cancer

NCT07421700

Q4 2028

PreclinicalRecruiting

Carcinoma, Hepatocellular

NCT07227012

PreclinicalRecruiting

Carcinoma, Renal Cell

NCT07227415

Q1 2031

Phase 2Not yet recruiting

Small Cell Lung Cancer

NCT07476287

Q3 2031

Phase 3Recruiting

Intestinal Neoplasm

NCT07222800

Phase 2Not yet recruiting

Locally Advanced

NCT07489066

Clinical

Trials by Indication[1]

Esophageal Cancer1 trial

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

Not yet recruiting· Pfizer logo

Pfizer·Phase 2/3·NCT07392892·840 enrolled

Locally Advanced1 trial

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

Not yet recruiting· Pfizer logo

Pfizer·Phase 2·NCT07489066·120 enrolled

Small Cell Lung Cancer1 trial

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

Not yet recruiting· Pfizer logo

Pfizer·Phase 2·NCT07476287·40 enrolled

Advanced Non-Small Cell Lung Cancer1 trial

AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT07222566·1,410 enrolled

Urothelial Cancer1 trial

AN INTERVENTIONAL PHASE 1B/2, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, ANTITUMOR ACTIVITY, AND PHARMACOKINETICS OF PF 08634404 MONOTHERAPY OR IN COMBINATION WITH ENFORTUMAB VEDOTIN IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER

Recruiting· Pfizer logo

Pfizer·Preclinical·NCT07421700·132 enrolled

5 more indications

Small Cell Lung Cancer ( SCLC )1 trial

A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

Recruiting· Pfizer logo

Pfizer·Preclinical·NCT07226999·550 enrolled

Non-Small Cell Lung Carcinoma1 trial

AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 IN COMBINATION WITH DIFFERENT ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Recruiting· Pfizer logo

Pfizer·Preclinical·NCT07227298·162 enrolled

Carcinoma, Renal Cell1 trial

AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA

Recruiting· Pfizer logo

Pfizer·Preclinical·NCT07227415·224 enrolled

Intestinal Neoplasm1 trial

AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT07222800·800 enrolled

Carcinoma, Hepatocellular1 trial

AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 AS MONOTHERAPY AND COMBINATION THERAPY IN ADULT PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA

Recruiting· Pfizer logo

Pfizer·Preclinical·NCT07227012·138 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for PF-08634404. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PF-08634404 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PF-08634404. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Pfizer

PF-08634404

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2028

Q1 2031

Q3 2031

Trials by Indication[1]

Esophageal Cancer1 trial

Locally Advanced1 trial

Small Cell Lung Cancer1 trial

Advanced Non-Small Cell Lung Cancer1 trial

Urothelial Cancer1 trial

Small Cell Lung Cancer ( SCLC )1 trial

Non-Small Cell Lung Carcinoma1 trial

Carcinoma, Renal Cell1 trial

Intestinal Neoplasm1 trial

Carcinoma, Hepatocellular1 trial

References

Drug Info

Quick Facts

Related News